Current Clinical Guidance

Filter Standards and Guidance documents

CEU Statement/Review Nexplanon Nov 2010

Nexplanon® [Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD), UK] is a progestogen-only subdermal implant that has now replaced the contraceptive implant, Implanon®. Nexplanon and Implanon are bioequivalent (i.e. they both contain 68 mg etonogestrel and they have the same release rate and 3-year duration of action). The main differences are that Nexplanon is radio-opaque and has a different application device and insertion technique.

This document is up-to-date

CEU Guidance Contraceptive Choices for Young People Mar 2010

This guidance is most relevant to young people under 18 years of age but may also apply to young people up to the age of 25 years. The guidance is intended for use by health professionals providing contraceptive services to young people.

This document is up-to-date

CEU Guidance Contraception for Women Over 40 Jul 2010

Contraceptive choice for women aged over 40 years may be influenced by many factors: frequency of intercourse, natural decline in fertility, sexual problems, the wish for noncontraceptive benefits, menstrual dysfunction and concurrent medical conditions.

This document is up-to-date

Statement from the FSRH Clinical Standards Committee, the Clinical Effectiveness Committee and the Associate Members’ Working Group on the prescription, administration or supply of Contraceptive Medicines for use outside the terms of their licences Dec 09

The above committees have agreed that Clinical Effectiveness Unit Guidance on use of contraceptives is guidance on “common practice” and “current practice” in the use of these medicines and devices. Therefore it is recommended that it may not be necessary for clinicians to document every occasion when a contraceptive preparation is prescribed outside the product licence if such use falls within current guidance issued by the Faculty’s Clinical Effectiveness Unit.

This document is up-to-date

CEU Guidance Problematic Bleeding with Hormonal Contraception Jul 2015

This guidance brings together evidence and expert opinion on the management of problematic bleeding in women using hormonal contraception [i.e. the combined oral contraceptive pill (COC), transdermal patch, combined vaginal ring (CVR), progestogen-only pill (POP), progestogen-only injectable, progestogen-only implant or intrauterine system (IUS)].

This document is up-to-date

CEU/BASHH Guidance Management of Vaginal Discharge in Non-Genitourinary Medicine Settings Feb 2012

This guidance provides information for health professionals working in non-genitourinary medicine (GUM) settings on management of vaginal discharge in women of reproductive age. Non-GUM settings include general practice, non-integrated or peripheral sexual health clinics and gynaecology clinics. The document has been produced by the Faculty of Sexual and Reproductive Healthcare (FSRH) in collaboration with the British Association for Sexual Health and HIV (BASHH).

This document is up-to-date

CEU Guidance Drug Interactions with Hormonal Contraception Jan 2012

This document provides guidance for health professionals on interactions between hormonal contraception and other drugs. Changes from previous Faculty guidance are summarised on pages ii and iii. This guidance does not consider the effects of underlying conditions on hormonal contraception. Recommendations are based on the evidence available at the time of writing and consensus opinion of experts.

This document is up-to-date

CEU Statement on newer Antiepileptic and Antiretrovial Drugs Mar 2013

The Clinical Effectiveness Unit (CEU) of the Faculty of Sexual and Reproductive Healthcare (FSRH) has received enquiries about two antiepileptic drugs (Fycompa® and Zebinix®) and an antiretroviral drug (Eviplera®). These drugs have become available in the UK since FSRH guidance on Drug Interactions with Hormonal Contraception was last updated.

This document is up-to-date

CEU Statement Quick Starting After UPA - Sept 2015

Faculty of Sexual and Reproductive Healthcare (FSRH) response to new data on quickstarting hormonal contraception after use of ulipristal acetate 30mg (ellaOne®) for emergency contraception Sept 2015.

This document is up-to-date

CEU Guidance Postnatal Sexual and Reproductive Health Sep 2009

This document provides guidance for health professionals on sexual and reproductive health in the postnatal period (i.e. delivery from 24 weeks gestation onwards). Recommendations are based on available evidence and consensus opinion of experts.

This document is up-to-date